Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2021-04-12 EFFECT View Document
2021-04-12 425 425 View Document
2021-04-12 6-K FORM 6-K View Document
2021-04-12 6-K CIRCULAR AND NOTICE OF GENERAL MEETING View Document
2021-04-12 425 425 View Document
2021-04-12 6-K UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL View Document
2021-04-09 F-4/A F-4/A View Document
2021-04-08 CORRESP View Document
2021-04-08 SC 13G SC 13G View Document
2021-04-01 425 425 View Document
2021-04-01 425 425 View Document
2021-04-01 425 425 View Document
2021-04-01 6-K TOTAL VOTING RIGHTS View Document
2021-03-30 6-K NOTICE OF AGM View Document
2021-03-30 6-K FORM 6-K View Document
2021-03-25 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-03-25 6-K AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACY View Document
2021-03-22 6-K ASTRAZENECA US VACCINE TRIAL MET PRIMARY ENDPOINT View Document
2021-03-16 4 4 View Document
2021-03-16 6-K DIVESTMENT OF VIELA SHAREHOLDING COMPLETED View Document
2021-03-16 6-K US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSES View Document
2021-03-12 425 425 View Document
2021-03-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-03-04 6-K DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES View Document
2021-03-03 6-K US COURT DECISION FAVOURS SYMBICORT PATENTS View Document
2021-03-02 6-K FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE View Document
2021-03-01 UPLOAD View Document
2021-03-01 6-K TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL View Document
2021-02-26 425 425 View Document
2021-02-25 425 425 View Document
2021-02-22 6-K VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US View Document
2021-02-19 F-4 F-4 View Document
2021-02-17 6-K LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA View Document
2021-02-16 IRANNOTICE IRANNOTICE View Document
2021-02-16 6-K FILING OF FORM 20-F WITH SEC View Document
2021-02-16 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-02-16 6-K ANNUAL FINANCIAL REPORT View Document
2021-02-16 20-F 20-F View Document
2021-02-12 425 425 View Document
2021-02-11 425 425 View Document
2021-02-11 425 425 View Document
2021-02-11 425 425 View Document
2021-02-11 425 425 View Document
2021-02-11 6-K ASTRAZENECA NON-EXECUTIVE BOARD CHANGES View Document
2021-02-11 6-K AZN: FULL-YEAR 2020 RESULTS View Document
2021-02-10 SC 13G SC 13G View Document
2021-02-10 SC 13G/A SC 13G/A View Document
2021-02-10 6-K DIVESTMENT OF CRESTOR IN EUROPE COMPLETED View Document
2021-02-05 6-K UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI View Document
2021-02-04 6-K FORXIGA APPROVED IN CHINA FOR HEART FAILURE View Document
2021-02-03 SC 13G/A SEC SCHEDULE 13G View Document
2021-02-01 6-K TOTAL VOTING RIGHTS View Document
2021-02-01 6-K ASTRAZENECA AGREES TO DIVEST VIELA SHAREHOLDING View Document
2021-02-01 6-K COVID-19 VACCINE AUTHORISED FOR USE BY THE EU View Document
2021-01-29 6-K COVID-19 VACCINE RECEIVES POSITIVE OPINION IN EU View Document
2021-01-29 SC 13G/A View Document
2021-01-26 6-K BLOCK LISTING APPLICATION View Document
2021-01-26 6-K SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA View Document
2021-01-25 6-K CALQUENCE APPROVED IN JAPAN FOR CLL View Document
2021-01-25 6-K CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB View Document
2021-01-20 6-K ENHERTU APPROVED IN THE EU FOR BREAST CANCER View Document
2021-01-19 6-K ENHERTU APPROVED IN THE US FOR GASTRIC CANCER View Document
2021-01-15 6-K IMFINZI APPROVED IN THE EU FOR LESS-FREQUENT, FIXED- DOSE USE IN UNRESECTABLE NO View Document
2021-01-06 6-K FARXIGA GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF PATIENTS WITH CHR View Document
2021-01-04 6-K TOTAL VOTING RIGHTS View Document
2021-01-04 6-K ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED View Document
2020-12-30 6-K ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK View Document
2020-12-29 6-K LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P View Document
2020-12-21 6-K TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST View Document
2020-12-21 6-K UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEAS View Document
2020-12-18 425 425 View Document
2020-12-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-12-17 425 425 View Document
2020-12-16 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-12-15 425 425 View Document
2020-12-15 6-K IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION View Document
2020-12-14 425 425 View Document
2020-12-14 425 425 View Document
2020-12-14 425 425 View Document
2020-12-14 425 425 View Document
2020-12-14 6-K TRASTUZUMAB DERUXTECAN POSITIVE CHMP View Document
2020-12-14 6-K TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPD View Document
2020-12-14 6-K ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC View Document
2020-12-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2020-12-01 6-K TOTAL VOTING RIGHTS View Document
2020-12-01 6-K CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE View Document
2020-11-30 6-K FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE View Document
2020-11-23 6-K AZD1222 VACCINE EFFECTIVE AGAINST COVID-19 View Document
2020-11-20 6-K IMFINZI NEW DOSING APPROVED IN THE US View Document
2020-11-13 25-NSE View Document
2020-11-10 6-K TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT View Document
2020-11-09 6-K CALQUENCE APPROVED IN THE EU FOR CLL View Document
2020-11-06 6-K BRILINTA APPROVED IN THE US IN STROKE View Document
2020-11-05 6-K AZN: YEAR-TO-DATE AND Q3 2020 RESULTS View Document
2020-11-05 6-K FORXIGA APPROVED IN THE EU FOR HEART FAILURE View Document
2020-11-05 6-K LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F View Document
2020-11-05 6-K LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRAT View Document
2020-11-02 6-K TOTAL VOTING RIGHTS View Document
2020-10-30 6-K ATACAND TO BE DIVESTED TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES View Document
2020-10-29 6-K DIRECTORATE CHANGE View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299